2020 Annual Meeting | C97 - Core Concepts in Pain Management: Refractory Neuropathic Pain Practical Pharmacologics, Advances in Neuromodulation, and a Balanced Look at Cannabinoids

Date Monday 04/27/20

Time 01:00 PM - 03:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) J M. Bailey, DO, PhD

Topic(s) Pain

Learning Objectives Participants should be able to discuss strategies to mitigate the failure of first line neuropathic pain adjuvants, understand second line pharmacologic and topical treatments, and the role of opioids in neuropathic pain treatment. Participants will understand the expanding types and targets of neuromodulation and where they fit in the treatment algorithm. Participants will understand the facts and fiction behind the use of cannabinoids in the treatment of neuropathic pain.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Case-based, Didactic, Audience Participation

Event Timeline
01:00 PM - 01:10 PM	Introduction	Introduction J M. Bailey, DO, PhD
01:10 PM - 01:40 PM	Speaker	Difficult to Treat Neuropathic Pain Charles E. Argoff, MD
01:40 PM - 02:10 PM	Speaker	Update on Interventional Pain Sahil Gupta, MD
02:10 PM - 02:40 PM	Speaker	THC/CBD: Role in Treatment of Pain Jessica Robinson Papp, MD, FAAN
02:40 PM - 03:00 PM	Discussion	Panel Discussion and Questions and Answers

Faculty Disclosures
J M. Bailey, DO, PhD	Dr. Bailey has nothing to disclose.
Charles E. Argoff, MD	Dr. Argoff has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Nevro. Dr. Argoff has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for XGene. Dr. Argoff has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vertex. Dr. Argoff has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Scilex. Dr. Argoff has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Colllegium. Dr. Argoff has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vertex. Dr. Argoff has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Allergan/Abbvie. Dr. Argoff has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Lundbeck. Dr. Argoff has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Scilex. Dr. Argoff has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Scilex. The institution of Dr. Argoff has received research support from Lilly. The institution of Dr. Argoff has received research support from Lundbeck. The institution of Dr. Argoff has received research support from Abbvie. The institution of Dr. Argoff has received research support from Vertex. Dr. Argoff has received publishing royalties from a publication relating to health care.
Sahil Gupta, MD	Dr. Gupta has nothing to disclose.
Jessica Robinson Papp, MD, FAAN	Dr. Robinson Papp has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Immgenuity Inc. Dr. Robinson Papp has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Neuropathix Inc. The institution of Dr. Robinson Papp has received research support from NIH. Dr. Robinson Papp has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��